The stock price of the skin beauty medical device specialist VIOL is down more than 6%.
According to the Korea Exchange, as of 9:19 a.m. on the 24th, VIOL's stock price is recorded at 7,500 won, down 5.78% (460 won) from the previous trading day.
The fact that its parent company, DMS, a display and semiconductor equipment corporation, received a 'disclaimer of opinion' in its 2024 audit report seems to be a negative factor putting it at risk of delisting.
The founder and largest shareholder of DMS, former CEO Park Yong-seok, and his two children, Park Hyun-ji and Park Hyun-seo, own 100% of Jeongbon Medical (formerly Jeongbon Global), which has become an issue.
The auditor, Dongseong Accounting Firm, noted in the audit report that it could not receive evidence to prove whether the transactions with Jeongbon Medical were normal transactions based on objective grounds.
The market believes that the delisting risk of DMS could spread to VIOL because DMS transferred its 100% subsidiary, Revenson, to Jeongbon Medical for about 4 billion won in 2023.
Meanwhile, Jeongbon Medical changed its name to its current name after merging with Revenson.